155 related articles for article (PubMed ID: 22397687)
1. The mGluR5 antagonist AFQ056 does not affect methylation and transcription of the mutant FMR1 gene in vitro.
Tabolacci E; Pirozzi F; Gomez-Mancilla B; Gasparini F; Neri G
BMC Med Genet; 2012 Mar; 13():13. PubMed ID: 22397687
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056.
Jacquemont S; Curie A; des Portes V; Torrioli MG; Berry-Kravis E; Hagerman RJ; Ramos FJ; Cornish K; He Y; Paulding C; Neri G; Chen F; Hadjikhani N; Martinet D; Meyer J; Beckmann JS; Delange K; Brun A; Bussy G; Gasparini F; Hilse T; Floesser A; Branson J; Bilbe G; Johns D; Gomez-Mancilla B
Sci Transl Med; 2011 Jan; 3(64):64ra1. PubMed ID: 21209411
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome.
Sheridan SD; Theriault KM; Reis SA; Zhou F; Madison JM; Daheron L; Loring JF; Haggarty SJ
PLoS One; 2011; 6(10):e26203. PubMed ID: 22022567
[TBL] [Abstract][Full Text] [Related]
4. CGG-repeat dynamics and
Zhou Y; Kumari D; Sciascia N; Usdin K
Mol Autism; 2016; 7():42. PubMed ID: 27713816
[TBL] [Abstract][Full Text] [Related]
5. microRNAs and Fragile X Syndrome.
Lin SL
Adv Exp Med Biol; 2015; 888():107-21. PubMed ID: 26663181
[TBL] [Abstract][Full Text] [Related]
6. Reciprocal changes in DNA methylation and hydroxymethylation and a broad repressive epigenetic switch characterize FMR1 transcriptional silencing in fragile X syndrome.
Brasa S; Mueller A; Jacquemont S; Hahne F; Rozenberg I; Peters T; He Y; McCormack C; Gasparini F; Chibout SD; Grenet O; Moggs J; Gomez-Mancilla B; Terranova R
Clin Epigenetics; 2016; 8():15. PubMed ID: 26855684
[TBL] [Abstract][Full Text] [Related]
7. Group I metabotropic glutamate receptor antagonists alter select behaviors in a mouse model for fragile X syndrome.
Thomas AM; Bui N; Perkins JR; Yuva-Paylor LA; Paylor R
Psychopharmacology (Berl); 2012 Jan; 219(1):47-58. PubMed ID: 21656124
[TBL] [Abstract][Full Text] [Related]
8. Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP.
Yan QJ; Rammal M; Tranfaglia M; Bauchwitz RP
Neuropharmacology; 2005 Dec; 49(7):1053-66. PubMed ID: 16054174
[TBL] [Abstract][Full Text] [Related]
9. Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome.
Osterweil EK; Krueger DD; Reinhold K; Bear MF
J Neurosci; 2010 Nov; 30(46):15616-27. PubMed ID: 21084617
[TBL] [Abstract][Full Text] [Related]
10. DNA Methylation, Mechanisms of
Nobile V; Pucci C; Chiurazzi P; Neri G; Tabolacci E
Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33669384
[TBL] [Abstract][Full Text] [Related]
11. AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome.
Levenga J; Hayashi S; de Vrij FM; Koekkoek SK; van der Linde HC; Nieuwenhuizen I; Song C; Buijsen RA; Pop AS; Gomezmancilla B; Nelson DL; Willemsen R; Gasparini F; Oostra BA
Neurobiol Dis; 2011 Jun; 42(3):311-7. PubMed ID: 21316452
[TBL] [Abstract][Full Text] [Related]
12. Role of CTCF protein in regulating FMR1 locus transcription.
Lanni S; Goracci M; Borrelli L; Mancano G; Chiurazzi P; Moscato U; Ferrè F; Helmer-Citterich M; Tabolacci E; Neri G
PLoS Genet; 2013; 9(7):e1003601. PubMed ID: 23874213
[TBL] [Abstract][Full Text] [Related]
13. Methylation of novel markers of fragile X alleles is inversely correlated with FMRP expression and FMR1 activation ratio.
Godler DE; Tassone F; Loesch DZ; Taylor AK; Gehling F; Hagerman RJ; Burgess T; Ganesamoorthy D; Hennerich D; Gordon L; Evans A; Choo KH; Slater HR
Hum Mol Genet; 2010 Apr; 19(8):1618-32. PubMed ID: 20118148
[TBL] [Abstract][Full Text] [Related]
14. The effect of an mGluR5 inhibitor on procedural memory and avoidance discrimination impairments in Fmr1 KO mice.
Vinueza Veloz MF; Buijsen RA; Willemsen R; Cupido A; Bosman LW; Koekkoek SK; Potters JW; Oostra BA; De Zeeuw CI
Genes Brain Behav; 2012 Apr; 11(3):325-31. PubMed ID: 22257369
[TBL] [Abstract][Full Text] [Related]
15. Fragile X syndrome: a preclinical review on metabotropic glutamate receptor 5 (mGluR5) antagonists and drug development.
Pop AS; Gomez-Mancilla B; Neri G; Willemsen R; Gasparini F
Psychopharmacology (Berl); 2014 Mar; 231(6):1217-26. PubMed ID: 24232444
[TBL] [Abstract][Full Text] [Related]
16. Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice.
Gantois I; Pop AS; de Esch CE; Buijsen RA; Pooters T; Gomez-Mancilla B; Gasparini F; Oostra BA; D'Hooge R; Willemsen R
Behav Brain Res; 2013 Feb; 239():72-9. PubMed ID: 23142366
[TBL] [Abstract][Full Text] [Related]
17. Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA.
Coffee B; Keith K; Albizua I; Malone T; Mowrey J; Sherman SL; Warren ST
Am J Hum Genet; 2009 Oct; 85(4):503-14. PubMed ID: 19804849
[TBL] [Abstract][Full Text] [Related]
18. Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/Mavoglurant.
Pop AS; Levenga J; de Esch CE; Buijsen RA; Nieuwenhuizen IM; Li T; Isaacs A; Gasparini F; Oostra BA; Willemsen R
Psychopharmacology (Berl); 2014 Mar; 231(6):1227-35. PubMed ID: 23254376
[TBL] [Abstract][Full Text] [Related]
19. Modest reactivation of the mutant FMR1 gene by valproic acid is accompanied by histone modifications but not DNA demethylation.
Tabolacci E; De Pascalis I; Accadia M; Terracciano A; Moscato U; Chiurazzi P; Neri G
Pharmacogenet Genomics; 2008 Aug; 18(8):738-41. PubMed ID: 18622267
[TBL] [Abstract][Full Text] [Related]
20. Quantitative analysis of DNA demethylation and transcriptional reactivation of the FMR1 gene in fragile X cells treated with 5-azadeoxycytidine.
Pietrobono R; Pomponi MG; Tabolacci E; Oostra B; Chiurazzi P; Neri G
Nucleic Acids Res; 2002 Jul; 30(14):3278-85. PubMed ID: 12136110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
